194 related articles for article (PubMed ID: 28586251)
1. The relationship between idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and autoimmunity.
Barcellini W
Expert Rev Hematol; 2017 Jul; 10(7):649-657. PubMed ID: 28586251
[TBL] [Abstract][Full Text] [Related]
2. Clinical evolution of autoimmune cytopenias to idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and bone marrow failure syndromes.
Barcellini W; Fattizzo B; Zaninoni A; Valli V; Ferri V; Gianelli U; Cortelezzi A
Am J Hematol; 2017 Mar; 92(3):E26-E29. PubMed ID: 28033669
[No Abstract] [Full Text] [Related]
3. Significance of Clonal Mutations in Bone Marrow Failure and Inherited Myelodysplastic Syndrome/Acute Myeloid Leukemia Predisposition Syndromes.
Schaefer EJ; Lindsley RC
Hematol Oncol Clin North Am; 2018 Aug; 32(4):643-655. PubMed ID: 30047417
[TBL] [Abstract][Full Text] [Related]
4. Introduction to Acquired and Inherited Bone Marrow Failure.
Sieff CA
Hematol Oncol Clin North Am; 2018 Aug; 32(4):569-580. PubMed ID: 30047411
[TBL] [Abstract][Full Text] [Related]
5. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS.
Valent P; Bain BJ; Bennett JM; Wimazal F; Sperr WR; Mufti G; Horny HP
Leuk Res; 2012 Jan; 36(1):1-5. PubMed ID: 21920601
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stem cells in immune-mediated bone marrow failure syndromes.
Kastrinaki MC; Pavlaki K; Batsali AK; Kouvidi E; Mavroudi I; Pontikoglou C; Papadaki HA
Clin Dev Immunol; 2013; 2013():265608. PubMed ID: 24386000
[TBL] [Abstract][Full Text] [Related]
7. Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5-azacytidine and literature review.
Frietsch JJ; Dornaus S; Neumann T; Scholl S; Schmidt V; Kunert C; Sayer HG; Hochhaus A; La Rosée P
Eur J Haematol; 2014 Sep; 93(3):247-59. PubMed ID: 24635656
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes.
Townsley DM; Desmond R; Dunbar CE; Young NS
Int J Hematol; 2013 Jul; 98(1):48-55. PubMed ID: 23690288
[TBL] [Abstract][Full Text] [Related]
9. Guest Editorial: Inherited bone marrow failure and myelodysplasia in children: how much do we know about pediatric diseases?
Manabe A
Int J Hematol; 2016 Apr; 103(4):359. PubMed ID: 26899856
[No Abstract] [Full Text] [Related]
10. Myelodysplastic syndrome accompanied by Addison's disease and multiple autoimmune phenomena: steroid therapy resolved cytopenias and all immune disorders.
Funato K; Kuriyama Y; Uchida Y; Suzuki A; Miyazawa K; Ohyashiki K
Intern Med; 2001 Oct; 40(10):1041-4. PubMed ID: 11688831
[TBL] [Abstract][Full Text] [Related]
11. An altered gut microbiota may trigger autoimmune-mediated acquired bone marrow failure syndromes.
Espinoza JL; Elbadry MI; Nakao S
Clin Immunol; 2016 Oct; 171():62-64. PubMed ID: 27506961
[No Abstract] [Full Text] [Related]
12. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP).
Malcovati L; Cazzola M
Hematology Am Soc Hematol Educ Program; 2015; 2015():299-307. PubMed ID: 26637737
[TBL] [Abstract][Full Text] [Related]
13. Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2014.
Visconte V; Lindsley RC; Berlyne D
Leuk Res; 2015 Jan; 39(1):110-3. PubMed ID: 25435026
[TBL] [Abstract][Full Text] [Related]
14. Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016.
Zeidan AM; Battiwalla M; Berlyne D; Winkler T
Leuk Res; 2017 Feb; 53():8-12. PubMed ID: 27923195
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin is highly effective in murine models of immune-mediated bone marrow failure.
Feng X; Lin Z; Sun W; Hollinger MK; Desierto MJ; Keyvanfar K; Malide D; Muranski P; Chen J; Young NS
Haematologica; 2017 Oct; 102(10):1691-1703. PubMed ID: 28729300
[TBL] [Abstract][Full Text] [Related]
16. [Bone marrow failure syndrome (idiopathic hematopoietic disorders): progress in diagnosis and treatment. Topics: III. Diagnosis and treatments; 3. Myelodysplastic syndrome].
Ichikawa M; Kurokawa M
Nihon Naika Gakkai Zasshi; 2012 Jul; 101(7):1945-52. PubMed ID: 22896998
[No Abstract] [Full Text] [Related]
17. ICUS/CCUS/CHIP: basics & beyond.
Jain M; Tripathi A
Expert Rev Hematol; 2017 Oct; 10(10):915-920. PubMed ID: 28832236
[TBL] [Abstract][Full Text] [Related]
18. Paroxysmal nocturnal hemoglobinuria clones are not infrequent in patients with inherited bone marrow failure syndromes.
Sreedharanunni S; Varma N; Sachdeva MUS; Naseem S; Malhotra P; Bansal D; Sood A; Bose P; Varma S
Eur J Haematol; 2017 Aug; 99(2):194-195. PubMed ID: 28452421
[No Abstract] [Full Text] [Related]
19. Genetic associations in acquired immune-mediated bone marrow failure syndromes: insights in aplastic anemia and chronic idiopathic neutropenia.
Mavroudi I; Papadaki HA
Clin Dev Immunol; 2012; 2012():123789. PubMed ID: 22956967
[TBL] [Abstract][Full Text] [Related]
20. Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.
Sun L; Babushok DV
Blood; 2020 Jul; 136(1):36-49. PubMed ID: 32430502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
